MeSH term
Frequency | Condition_Probility | Antigens, CD/blood | 2 | 0.0 |
Cells, Cultured | 28 | 0.0 |
Humans | 249 | 0.0 |
Interleukin-2/*pharmacology | 16 | 6.0 |
Lymphocyte Activation | 13 | 0.0 |
*Milk Proteins | 47 | 10.0 |
Phosphorylation | 83 | 1.0 |
Phosphotyrosine | 9 | 3.0 |
Research Support, Non-U.S. Gov't | 171 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 84 | 0.0 |
Animals | 117 | 0.0 |
Mice | 70 | 0.0 |
Mice, SCID | 4 | 0.0 |
Phosphotyrosine/metabolism | 13 | 3.0 |
Protein-Tyrosine Kinase/*metabolism | 59 | 7.0 |
Signal Transduction | 60 | 1.0 |
Cytokines/pharmacology | 2 | 0.0 |
Disease Models, Animal | 4 | 0.0 |
In Vitro | 3 | 0.0 |
Mice, Inbred C57BL | 7 | 0.0 |
Mice, Knockout | 6 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Protein-Tyrosine Kinase/*deficiency/genetics | 3 | 50.0 |
B-Lymphocytes/*metabolism | 7 | 3.0 |
Blotting, Western | 12 | 0.0 |
Cell Separation | 2 | 0.0 |
Flow Cytometry | 7 | 0.0 |
Interleukin-4/*metabolism | 4 | 10.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Models, Genetic | 2 | 0.0 |
Precipitin Tests | 16 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
Trans-Activators/metabolism | 35 | 3.0 |
Transfection | 39 | 0.0 |
Tumor Cells, Cultured | 41 | 0.0 |
Alternative Splicing | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 22 | 1.0 |
Gene Expression Profiling | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Mutation | 14 | 0.0 |
Quinazolines/pharmacology | 4 | 5.0 |
*Signal Transduction | 35 | 1.0 |
Trans-Activators/*metabolism | 27 | 2.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 6 | 1.0 |
*Adaptor Proteins, Signal Transducing | 10 | 0.0 |
*Adaptor Proteins, Vesicular Transport | 2 | 0.0 |
Apoptosis/drug effects | 3 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Drug Synergism | 3 | 0.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
MAP Kinase Kinase 1 | 2 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 4 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 37 | 3.0 |
Signal Transduction/*drug effects | 13 | 3.0 |
Time Factors | 10 | 0.0 |
Administration, Oral | 2 | 0.0 |
B-Lymphocytes/drug effects/immunology | 2 | 6.0 |
Female | 21 | 0.0 |
Male | 27 | 0.0 |
*Apoptosis | 2 | 0.0 |
Cell Line | 69 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Proto-Oncogene Protein pp60(c-src)/physiology | 2 | 25.0 |
Up-Regulation | 7 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 12 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 3 | 1.0 |
Trans-Activation (Genetics)/drug effects | 3 | 1.0 |
COS Cells | 18 | 0.0 |
Hela Cells | 6 | 0.0 |
Amino Acid Sequence | 34 | 0.0 |
B-Lymphocytes/metabolism | 3 | 1.0 |
Cell Line, Transformed | 17 | 1.0 |
Child | 6 | 0.0 |
DNA, Complementary | 5 | 0.0 |
Gene Expression | 7 | 0.0 |
Immunophenotyping | 6 | 0.0 |
Interleukin-2/metabolism | 4 | 2.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Molecular Sequence Data | 59 | 0.0 |
Pedigree | 2 | 0.0 |
Receptors, Interleukin-2/metabolism | 7 | 3.0 |
Sequence Analysis, DNA | 8 | 0.0 |
T-Lymphocytes | 3 | 1.0 |
Comparative Study | 25 | 0.0 |
DNA-Binding Proteins/metabolism | 25 | 1.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism | 3 | 5.0 |
Phosphorylation/drug effects | 16 | 1.0 |
Protein Processing, Post-Translational/*drug effects | 5 | 9.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 8 | 5.0 |
*Proto-Oncogene Proteins | 49 | 2.0 |
Rats | 13 | 0.0 |
T-Lymphocytes/*drug effects/enzymology | 3 | 30.0 |
3T3 Cells | 5 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Enzyme Activation | 36 | 1.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Protein Binding | 21 | 0.0 |
Tyrosine/metabolism | 26 | 2.0 |
Cell Division | 17 | 0.0 |
Dimerization | 5 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 5 | 0.0 |
Models, Biological | 7 | 0.0 |
Receptors, Antigen, T-Cell/metabolism | 2 | 1.0 |
Receptors, Interleukin-2/*metabolism | 10 | 13.0 |
Transcription, Genetic | 8 | 0.0 |
Catalysis | 3 | 0.0 |
Models, Molecular | 10 | 0.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Receptors, Interleukin-7/genetics/metabolism | 2 | 100.0 |
Sequence Alignment | 3 | 0.0 |
*Cell Transformation, Viral | 2 | 1.0 |
Gene Deletion | 6 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Consanguinity | 4 | 1.0 |
DNA Mutational Analysis | 6 | 0.0 |
Exons | 7 | 0.0 |
Genotype | 3 | 0.0 |
Infant | 10 | 0.0 |
Interleukin-2/pharmacology | 17 | 3.0 |
Introns | 7 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Phenotype | 11 | 0.0 |
Protein-Tyrosine Kinase/chemistry/*genetics/*metabolism | 2 | 28.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Protein Conformation | 5 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 6 | 1.0 |
Cell Transformation, Viral | 2 | 0.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Macromolecular Substances | 13 | 0.0 |
Protein Processing, Post-Translational | 6 | 0.0 |
Proteins/genetics/*physiology | 2 | 1.0 |
Structure-Activity Relationship | 9 | 0.0 |
TNF Receptor-Associated Factor 2 | 3 | 1.0 |
Tyrosine/chemistry | 3 | 2.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Binding Sites | 14 | 0.0 |
Down-Regulation | 5 | 0.0 |
Jurkat Cells | 4 | 0.0 |
Point Mutation | 6 | 0.0 |
T-Lymphocytes/*immunology | 8 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
src Homology Domains | 7 | 1.0 |
Antigens, CD/*metabolism | 2 | 0.0 |
Cytoplasm/metabolism | 4 | 0.0 |
Fibrosarcoma | 3 | 6.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 10 | 7.0 |
Antibodies, Monoclonal/immunology | 4 | 0.0 |
Membrane Microdomains/*physiology | 2 | 10.0 |
Protein-Tyrosine Kinase/physiology | 4 | 3.0 |
Signal Transduction/drug effects/physiology | 5 | 2.0 |
Antigens, CD3/metabolism | 2 | 1.0 |
Apoptosis | 3 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology/*virology | 2 | 13.0 |
Cell Division/drug effects | 11 | 0.0 |
Signal Transduction/drug effects | 6 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Adult | 7 | 0.0 |
Aged | 2 | 0.0 |
DNA-Binding Proteins/analysis | 2 | 2.0 |
Middle Aged | 4 | 0.0 |
Protein-Tyrosine Kinase/*analysis | 2 | 6.0 |
Receptors, Interleukin/*physiology | 3 | 12.0 |
Signal Transduction/genetics/immunology | 2 | 2.0 |
Protein-Tyrosine Kinase/*physiology | 6 | 4.0 |
Trans-Activators/chemistry/*metabolism | 2 | 3.0 |
Transcription Factors/physiology | 2 | 0.0 |
Interleukin-7/*physiology | 2 | 22.0 |
B-Lymphocytes | 2 | 1.0 |
Herpesvirus 4, Human | 3 | 2.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Signal Transduction/*physiology | 8 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Cytokines/*metabolism | 2 | 0.0 |
Rabbits | 4 | 0.0 |
Biopsy | 2 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
DNA/metabolism | 7 | 0.0 |
DNA-Binding Proteins/physiology | 3 | 1.0 |
Trans-Activators/physiology | 5 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Signal Transduction/drug effects/*immunology | 4 | 10.0 |
B-Lymphocytes/immunology | 5 | 0.0 |
Immunoblotting | 4 | 0.0 |
Killer Cells, Natural/immunology | 4 | 0.0 |
T-Lymphocytes/immunology | 6 | 0.0 |
X Chromosome | 5 | 1.0 |
Interleukin-2/antagonists & inhibitors/physiology | 2 | 50.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors/metabolism | 5 | 12.0 |
Serine/metabolism | 2 | 0.0 |
Receptors, Interleukin-2/genetics | 4 | 10.0 |
Tyrphostins/pharmacology | 4 | 2.0 |
DNA-Binding Proteins/antagonists & inhibitors | 2 | 13.0 |
Enzyme Activation/drug effects | 10 | 1.0 |
Interleukin-2/*physiology | 7 | 9.0 |
*Intracellular Signaling Peptides and Proteins | 5 | 0.0 |
Interleukin-13/*pharmacology | 5 | 11.0 |
Interleukin-4/*pharmacology | 13 | 5.0 |
Phosphoproteins/metabolism | 8 | 1.0 |
Genes, Reporter | 5 | 0.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Heterozygote | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Protein-Tyrosine Kinase/deficiency/*genetics | 3 | 50.0 |
Severe Combined Immunodeficiency/*genetics | 3 | 13.0 |
*Mutation | 6 | 0.0 |
Base Sequence | 44 | 0.0 |
Gene Expression Regulation | 5 | 0.0 |
Phylogeny | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 13 | 6.0 |
Proteins/genetics | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Infant, Newborn | 6 | 0.0 |
Trans-Activation (Genetics)/*physiology | 2 | 1.0 |
DNA/genetics/metabolism | 5 | 1.0 |
DNA-Binding Proteins/antagonists & inhibitors/*metabolism | 2 | 7.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Trans-Activators/antagonists & inhibitors/*metabolism | 2 | 8.0 |
Cloning, Molecular | 12 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 4 | 1.0 |
Substrate Specificity | 6 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Protein-Tyrosine-Phosphatase/*physiology | 3 | 11.0 |
Receptors, Interleukin-2/drug effects/*metabolism | 2 | 40.0 |
Cell Division/physiology | 3 | 0.0 |
Enzyme Inhibitors/*chemical synthesis/pharmacology | 2 | 11.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Apoptosis/*physiology | 2 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Catalytic Domain | 2 | 0.0 |
Cytokines/metabolism | 3 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 2 | 1.0 |
Interleukin-3/metabolism | 2 | 6.0 |
*Repressor Proteins | 4 | 0.0 |
Carcinoma, Renal Cell/*immunology | 2 | 11.0 |
Interferon Type II/biosynthesis | 3 | 0.0 |
Interleukin-2/*biosynthesis | 2 | 1.0 |
Kidney Neoplasms/*immunology | 2 | 7.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Receptors, Interleukin-2/*physiology | 3 | 13.0 |
Lymphocyte Activation/drug effects | 4 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Severe Combined Immunodeficiency/enzymology/*genetics | 4 | 80.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Gene Expression Regulation/drug effects/*immunology | 2 | 6.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Trans-Activators/genetics/*metabolism | 5 | 1.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Enzyme Inhibitors/*therapeutic use | 2 | 2.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Keratinocytes/metabolism | 2 | 1.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Receptors, Interleukin/*metabolism | 3 | 9.0 |
Severe Combined Immunodeficiency/enzymology/*genetics/immunology | 2 | 66.0 |
Exons/*genetics | 2 | 0.0 |
Introns/*genetics | 2 | 1.0 |
Disease Progression | 2 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Biological Transport | 3 | 0.0 |
Cell Nucleus/metabolism | 7 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/analysis/*metabolism | 2 | 28.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
Quinazolines/*pharmacology | 5 | 5.0 |
Chromosome Mapping | 6 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Polymerase Chain Reaction | 12 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
DNA Primers | 7 | 0.0 |
Receptors, Interleukin-2/chemistry/genetics/*metabolism | 2 | 66.0 |
Cell Differentiation | 4 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 4 | 0.0 |
Interleukin-4/*physiology | 6 | 13.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Binding Sites/drug effects | 2 | 3.0 |
Computer Simulation | 2 | 0.0 |
Drug Design | 5 | 1.0 |
DNA-Binding Proteins/biosynthesis | 2 | 2.0 |
*Mitogen-Activated Protein Kinases | 4 | 1.0 |
Protein Biosynthesis | 2 | 0.0 |
Protein-Tyrosine Kinase/biosynthesis | 2 | 8.0 |
Rats, Wistar | 3 | 0.0 |
Transcription Factors/biosynthesis | 2 | 2.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Lymphocyte Activation/immunology | 4 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism/*physiology | 2 | 16.0 |
Tyrphostins/*pharmacology | 2 | 8.0 |
Cytokines/physiology | 4 | 2.0 |
Molecular Structure | 3 | 0.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
Severe Combined Immunodeficiency/enzymology/genetics | 2 | 100.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Tyrosine/*metabolism | 4 | 1.0 |
Leukemia/pathology | 2 | 6.0 |
Immunosuppressive Agents/pharmacology | 2 | 1.0 |
Transcription, Genetic/drug effects/immunology | 2 | 12.0 |
*Immune Tolerance | 3 | 1.0 |
src-Family Kinases/metabolism | 5 | 2.0 |
Protein-Tyrosine Kinase/*biosynthesis/genetics | 2 | 18.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
*Point Mutation | 2 | 0.0 |
Protein-Tyrosine Kinase/*genetics/metabolism | 3 | 6.0 |
Protein Kinases/*metabolism | 3 | 0.0 |
*Gene Expression Regulation | 4 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Proteins/*metabolism | 5 | 0.0 |
Signal Transduction/immunology | 7 | 2.0 |
Cytokines/*physiology | 3 | 1.0 |
Mammals | 2 | 0.0 |
Receptors, Cytokine/*physiology | 3 | 11.0 |
CD40 Ligand | 2 | 1.0 |
Coculture Techniques | 2 | 0.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Ligands | 6 | 0.0 |
Bone Marrow Transplantation | 2 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Gene Therapy/*methods | 2 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Interleukin-13/pharmacology/*physiology | 2 | 28.0 |
Receptors, Cytokine/metabolism | 2 | 2.0 |
Clone Cells | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism/*physiology | 3 | 11.0 |
Enzyme Induction | 4 | 0.0 |
Interleukin-13/*pharmacology/physiology | 2 | 40.0 |
Monocytes/drug effects/*enzymology | 2 | 22.0 |
Linkage (Genetics) | 4 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/genetics | 2 | 4.0 |
Bone Marrow Transplantation/methods | 2 | 33.0 |
Interleukin-4/pharmacology | 8 | 2.0 |
Cross-Linking Reagents | 2 | 0.0 |
Interleukin-13/metabolism/*pharmacology | 2 | 33.0 |
Proteins/metabolism | 9 | 0.0 |
Receptors, Interleukin/genetics/*metabolism | 2 | 25.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
Signal Transduction/*immunology | 6 | 1.0 |
Trans-Activators/biosynthesis/*metabolism | 2 | 13.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Interferon Type II/physiology | 2 | 2.0 |
Lymphocyte Activation/*physiology | 3 | 3.0 |
T-Lymphocytes/enzymology/*immunology | 2 | 9.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Gene Library | 3 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Interleukin-9/*pharmacology | 3 | 37.0 |
Kinetics | 4 | 0.0 |
Interleukin-2/*immunology | 2 | 3.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Interleukin-2/*metabolism | 2 | 4.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Cytokines/secretion | 2 | 2.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Protein-Tyrosine Kinase/biosynthesis/*deficiency/*genetics | 2 | 66.0 |
Retroviridae | 2 | 2.0 |
Adjuvants, Immunologic/physiology | 2 | 4.0 |
Signal Transduction/physiology | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase | 3 | 2.0 |
Antigens, CD/metabolism | 4 | 0.0 |
Enzyme Activation/immunology | 2 | 1.0 |
Receptors, Interleukin/metabolism | 4 | 6.0 |
Receptors, Interleukin-7 | 3 | 17.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Skin Neoplasms/*metabolism/pathology | 2 | 3.0 |
*Tyrphostins | 2 | 3.0 |
B-Lymphocytes/enzymology | 3 | 8.0 |
Hematopoietic Stem Cells/*enzymology | 2 | 6.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
*Chromosomes, Human, Pair 19 | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Cell Survival | 3 | 0.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 6 | 2.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 2 | 2.0 |
Receptors, Interleukin-4 | 11 | 16.0 |
T-Lymphocytes/*metabolism | 7 | 1.0 |
Conserved Sequence | 2 | 0.0 |
Interleukin-2/pharmacology/*physiology | 2 | 28.0 |
Receptors, Interleukin/physiology | 3 | 20.0 |
Phosphoproteins/*metabolism | 3 | 0.0 |
Fetal Blood/cytology | 2 | 1.0 |
B-Lymphocytes/*immunology/metabolism | 2 | 4.0 |
Receptors, Antigen, T-Cell/*physiology | 2 | 1.0 |
Genes, Recessive | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
*Exons | 2 | 0.0 |
Polyenes/pharmacology | 2 | 7.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Sirolimus | 2 | 4.0 |
Stimulation, Chemical | 2 | 0.0 |
Tacrolimus/pharmacology | 2 | 4.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Receptors, Interleukin-2/biosynthesis/*physiology | 2 | 66.0 |
T-Lymphocytes/*immunology/*metabolism | 2 | 6.0 |
Interleukin-4/metabolism | 3 | 3.0 |
Receptors, Interleukin-2/physiology | 2 | 4.0 |
*Lymphocyte Activation | 3 | 0.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Interleukin-12/*pharmacology | 2 | 4.0 |
Organ Specificity | 2 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
*Gene Therapy | 3 | 0.0 |
Interleukin-15 | 2 | 22.0 |
Cercopithecus aethiops | 3 | 0.0 |
Hematopoiesis | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Hematopoietic Stem Cells | 2 | 3.0 |
Chromosome Aberrations | 2 | 0.0 |
Models, Structural | 2 | 1.0 |
Receptors, Interleukin-2/chemistry/*metabolism | 4 | 57.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Interleukin-7/*pharmacology | 2 | 4.0 |
Nitriles/pharmacology | 2 | 1.0 |
Proto-Oncogene Proteins c-myc/biosynthesis | 2 | 6.0 |
Tyrosine/analogs & derivatives/metabolism | 4 | 3.0 |
Tyrosine/analogs & derivatives/analysis/metabolism | 2 | 18.0 |
Cell Cycle | 4 | 0.0 |
Receptor, erbB-2/metabolism | 2 | 1.0 |
T-Lymphocytes/*enzymology/metabolism | 2 | 33.0 |
Receptors, Interleukin-2/genetics/*metabolism | 2 | 28.0 |
Cell Line, Tumor | 3 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
Signal Transduction/drug effects/immunology | 2 | 4.0 |
English Abstract | 2 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Ubiquitin/metabolism | 2 | 0.0 |
Antigens, CD40/physiology | 2 | 6.0 |
